# Sleep Disorders in the Elderly

## Introduction

Sleep complaints are among the most common health concerns reported by older adults, affecting 40 to 70 percent of individuals aged 65 and older. Insomnia is the most prevalent sleep disorder in this population, though obstructive sleep apnea, restless legs syndrome, and REM sleep behavior disorder also occur with significant frequency and clinical impact. The consequences of disordered sleep extend far beyond daytime fatigue and irritability. Poor sleep quality and insufficient sleep duration are independently associated with cognitive decline, depression, falls, cardiovascular disease, immune dysfunction, and increased mortality, making sleep health an essential domain of comprehensive geriatric care.

Despite the high prevalence and serious consequences of sleep disorders in the elderly, these conditions are frequently either undertreated or treated inappropriately. The reflexive prescription of benzodiazepines and non-benzodiazepine receptor agonists (Z-drugs) persists despite overwhelming evidence that these agents are harmful in the elderly, increasing the risk of falls, cognitive impairment, delirium, and dependence. The most important clinical message is that insomnia is a treatable condition and that cognitive behavioral therapy for insomnia (CBT-I) is the recommended first-line treatment, demonstrating superior long-term efficacy compared with any pharmacological intervention.

## Normal Age-Related Sleep Changes

Understanding the normal sleep changes that accompany aging is essential for distinguishing physiological adaptation from pathological sleep disturbance. Total sleep time decreases modestly from 7 to 8 hours in young adults to approximately 6 to 6.5 hours in healthy elderly individuals. Sleep efficiency, defined as the ratio of time asleep to time in bed, decreases from approximately 95 percent in young adults to 80 to 85 percent in the elderly. Sleep latency, the time required to fall asleep, increases slightly. Nighttime awakenings become more frequent, increasing the wake-after-sleep-onset (WASO) metric and producing the subjective experience of fragmented, non-restorative sleep.

The architecture of sleep itself undergoes characteristic changes with aging. Slow-wave sleep (N3 or deep sleep) decreases substantially from approximately 20 percent of total sleep time in young adults to 5 to 10 percent in the elderly, reducing the amount of the most physiologically restorative sleep stage. REM sleep is relatively preserved but may decrease modestly. The circadian timing system shifts, producing an advanced circadian phase with earlier sleep onset and earlier morning awakening, a pattern known as advanced sleep phase syndrome. The amplitude of melatonin secretion decreases, contributing to circadian rhythm disruption. These changes are normal aspects of aging and do not constitute insomnia unless they produce significant distress or daytime impairment. Counseling patients that a modest reduction in total sleep time and slightly lighter sleep are normal aspects of aging can prevent unnecessary concern and inappropriate treatment.

## Insomnia

### Diagnosis (ICSD-3 Criteria)

The International Classification of Sleep Disorders, Third Edition, defines insomnia as difficulty initiating sleep, difficulty maintaining sleep, or early morning awakening that occurs despite adequate opportunity and circumstances for sleep and that causes clinically significant daytime impairment, including fatigue, mood disturbance, cognitive impairment, or functional impairment. Chronic insomnia is defined by the persistence of symptoms on at least 3 nights per week for 3 months or longer.

### Contributing Factors in Elderly

Insomnia in the elderly is typically multifactorial, arising from the convergence of medical, psychiatric, pharmacological, behavioral, environmental, and primary sleep disorder contributions. Medical conditions that frequently disrupt sleep include pain from arthritis or neuropathy, gastroesophageal reflux disease, nocturia from benign prostatic hyperplasia, overactive bladder, or heart failure, dyspnea from COPD or heart failure, and pruritus. Psychiatric conditions, particularly depression with its characteristic early morning awakening and anxiety with its sleep-onset insomnia, are major contributors. PTSD and bereavement-related distress are additional psychiatric causes.

Medications represent a substantial and modifiable cause of insomnia in the elderly. Stimulants including caffeine and methylphenidate, beta-blockers (which can cause nightmares and sleep disruption), diuretics (which exacerbate nocturia), corticosteroids, SSRIs, theophylline, and decongestants all have the potential to impair sleep quality. Behavioral factors, including excessive time spent in bed, daytime napping, irregular sleep-wake schedules, screen time before bed, and use of caffeine or alcohol, frequently perpetuate insomnia. Environmental factors such as noise, light, uncomfortable temperature, bed partner disturbance, and the institutional setting of a hospital or nursing home further contribute. Primary sleep disorders, including sleep apnea, restless legs syndrome, and circadian rhythm disorders, must be identified and treated when present.

### Management

#### CBT-I — First-Line Treatment (ACP, AASM Guidelines)

Cognitive behavioral therapy for insomnia is the recommended first-line treatment for chronic insomnia in the elderly, endorsed by both the American College of Physicians and the American Academy of Sleep Medicine. CBT-I is more effective than medication for chronic insomnia in the elderly, and its benefits persist long after treatment cessation, a critical advantage over pharmacotherapy, which provides symptom relief only during active use and carries the risk of rebound insomnia upon discontinuation.

CBT-I is typically delivered over 4 to 8 sessions by a trained therapist, though digital platforms such as SHUTi and Somryst offer validated alternatives when in-person therapy is unavailable. The intervention comprises five components. Sleep restriction limits the time spent in bed to the actual sleep time, creating mild sleep deprivation that consolidates fragmented sleep and improves sleep efficiency. For example, a patient sleeping 5 hours but spending 9 hours in bed would have their time in bed restricted to 5.5 hours, with gradual extension as sleep efficiency improves toward the target of 85 percent or greater. In elderly patients, sleep restriction must be implemented cautiously because the initial mild sleep deprivation may worsen daytime fatigue and increase fall risk.

Stimulus control re-establishes the association between the bed and sleep by restricting bed use to sleep and sexual activity only. The patient is instructed that if they are unable to fall asleep within 20 minutes, they should get up, leave the bedroom, and return only when feeling sleepy. A fixed wake time is maintained daily regardless of how much sleep was obtained. Cognitive restructuring addresses maladaptive beliefs about sleep, such as "I must get 8 hours" or "I will be unable to function if I don't sleep," replacing them with more realistic and adaptive cognitions. Sleep hygiene education covers the maintenance of a regular schedule, a dark, quiet, and cool sleep environment, avoidance of screens before bed, limitation of caffeine after noon, and avoidance of alcohol as a sleep aid. Relaxation training, including progressive muscle relaxation, guided imagery, and diaphragmatic breathing, provides additional tools for reducing the physiological arousal that perpetuates insomnia.

Meta-analyses demonstrate sustained improvement with CBT-I, including reductions in sleep latency of 20 minutes, reductions in WASO of 30 minutes, improvements in sleep efficiency of 10 percent, and improvements in subjective sleep quality, all of which are superior to pharmacotherapy outcomes at 12 months.

#### Pharmacological Treatment (Second-Line)

Pharmacological treatment should be employed only when CBT-I is unavailable, insufficient, or refused. When medications are prescribed, they should be used at the lowest effective dose for the shortest possible duration, typically no longer than 4 weeks, with regular reassessment of continued need.

##### Melatonin and Melatonin Receptor Agonists

Exogenous melatonin at low doses of 0.5 to 3 mg, taken 1 to 2 hours before the desired bedtime, is most useful for circadian rhythm disorders and produces a modest reduction in sleep latency of approximately 7 minutes. Higher doses are not more effective. Melatonin is well-tolerated with minimal side effects and no dependence liability. Extended-release melatonin at 2 mg (Circadin), approved in Europe for insomnia in adults aged 55 and older, has shown improvement in sleep quality.

Ramelteon, a melatonin receptor (MT1/MT2) agonist dosed at 8 mg at bedtime, reduces sleep latency without abuse potential or next-day sedation. Its efficacy for sleep maintenance is limited, and its overall effect size is modest. The dual orexin receptor antagonists, suvorexant and lemborexant, represent an emerging preferred pharmacotherapy for elderly patients. Suvorexant at 10 mg at bedtime (starting low in the elderly) and lemborexant at 5 mg improve both sleep onset and sleep maintenance. They do not produce physical dependence or rebound insomnia. Side effects include next-day somnolence, rare sleep paralysis, and the potential for complex sleep behaviors. Their favorable safety profile relative to benzodiazepines and Z-drugs has positioned them as the pharmacological agents of choice when medication is needed for insomnia in the elderly.

| Sleep Medication | Dose in Elderly | Mechanism | Safety Profile | Recommended Status |
|-----------------|----------------|-----------|---------------|-------------------|
| Melatonin | 0.5–3 mg | MT1/MT2 agonist | Excellent; no dependence | Preferred — circadian disorders |
| Ramelteon | 8 mg | MT1/MT2 agonist | Good; no abuse potential | Preferred — sleep-onset insomnia |
| Suvorexant | 10 mg | Dual orexin receptor antagonist | Good; no physical dependence | Emerging preferred — onset + maintenance |
| Lemborexant | 5 mg | Dual orexin receptor antagonist | Good; no physical dependence | Emerging preferred — onset + maintenance |
| Trazodone | 25–50 mg | 5-HT2A antagonist | Moderate; orthostatic hypotension | Commonly used; weak evidence |
| Low-dose doxepin | 3–6 mg | H1 antagonist | Moderate; sedating | FDA-approved for sleep maintenance |

##### Agents to AVOID or Use with Extreme Caution

Benzodiazepines, including temazepam, lorazepam, and triazolam, should be avoided in elderly patients as recommended by the Beers Criteria. These agents increase fall risk by an odds ratio of 1.5 to 2.0, impair cognition, depress respiration, produce dependence, precipitate delirium, cause next-day sedation, and produce rebound insomnia upon discontinuation. Z-drugs, including zolpidem, eszopiclone, and zaleplon, carry risks similar to benzodiazepines despite their marketing as safer alternatives. Zolpidem is specifically associated with falls, driving impairment, and complex sleep behaviors including sleepwalking, sleep-eating, and sleep-driving. The FDA reduced the recommended dose of zolpidem to 5 mg for women and elderly patients. The Beers Criteria classify Z-drugs as potentially inappropriate in the elderly.

Antihistamines, including diphenhydramine, doxylamine, and hydroxyzine, should be avoided due to strong anticholinergic effects that produce cognitive impairment, delirium, urinary retention, constipation, and next-day sedation. Trazodone at 25 to 50 mg at bedtime is commonly used off-label for insomnia and offers the advantages of no abuse potential, modest sedation, and antidepressant properties. However, it carries risks of orthostatic hypotension, rare priapism, and next-day sedation, and the evidence base for its use as a primary insomnia treatment is weak despite extensive clinical experience.

<image>A treatment algorithm for insomnia in elderly patients. Start with "Insomnia symptoms ≥3 nights/week for ≥3 months with daytime impairment." First step: "Identify and address contributing factors" — show a checklist: pain, nocturia, medications, depression/anxiety, sleep apnea, RLS, caffeine/alcohol, environmental factors. Second step: "CBT-I — FIRST-LINE" — show the 5 components (sleep restriction, stimulus control, cognitive restructuring, sleep hygiene, relaxation) with expected outcomes (sleep latency -20 min, WASO -30 min, maintained at 12 months). If CBT-I insufficient or unavailable: "Pharmacotherapy — SECOND-LINE, short-term." Show a traffic light medication guide: GREEN (preferred in elderly): melatonin 0.5-3 mg, ramelteon 8 mg, suvorexant/lemborexant 5-10 mg, trazodone 25-50 mg (weak evidence). YELLOW (caution): low-dose doxepin 3-6 mg. RED (AVOID): benzodiazepines, Z-drugs (zolpidem, eszopiclone), diphenhydramine, hydroxyzine. Include a note: "If already on benzodiazepine/Z-drug → taper gradually over 6-12 weeks with CBT-I support."</image>

## Obstructive Sleep Apnea (OSA)

### Prevalence and Significance

Obstructive sleep apnea is extraordinarily common in elderly populations, with prevalence estimates ranging from 30 to 80 percent depending on the diagnostic threshold applied. Traditional risk factors include obesity, male sex (though this differential equalizes after menopause), craniofacial anatomy, and tonsillar hypertrophy. The consequences of untreated OSA are broad and include excessive daytime sleepiness, cognitive impairment, hypertension, cardiac arrhythmias (particularly atrial fibrillation), stroke, heart failure, and nocturia. OSA is markedly underdiagnosed in the elderly because the clinical presentation may be atypical, featuring cognitive decline, nocturia, or insomnia rather than the classic presentation of loud snoring and excessive daytime sleepiness.

### Diagnosis

In-laboratory polysomnography remains the gold standard for OSA diagnosis. Home sleep apnea testing is an acceptable alternative for uncomplicated suspected OSA but has reduced sensitivity in elderly patients. The apnea-hypopnea index classifies OSA severity, with an AHI of 5 or greater indicating mild, 15 or greater indicating moderate, and 30 or greater indicating severe disease. The STOP-BANG questionnaire, with a score of 3 or more indicating high risk, provides useful screening. The Epworth Sleepiness Scale, with a score of 10 or more indicating excessive daytime sleepiness, quantifies the functional impact of the disorder.

### Treatment

Continuous positive airway pressure is the first-line treatment for moderate-to-severe OSA. CPAP reduces daytime sleepiness and improves cognitive function and quality of life. Adherence remains the primary challenge in elderly patients, with 40 to 60 percent adherence at one year. Strategies to improve adherence include careful mask fitting, heated humidification, behavioral support, pressure ramping, and auto-titrating CPAP devices. Oral appliances (mandibular advancement devices) are appropriate for mild-to-moderate OSA or when CPAP is not tolerated, though they are less effective than CPAP. Positional therapy, consisting of measures to maintain lateral sleeping position, is appropriate when OSA is predominantly supine. Weight loss, even modest amounts, reduces the AHI in obese patients. Surgical options, including uvulopalatopharyngoplasty, are less commonly pursued in elderly patients. Hypoglossal nerve stimulation (Inspire device) is available for moderate-to-severe OSA in patients who have failed CPAP and have a BMI below 32.

## Restless Legs Syndrome (RLS) / Willis-Ekbom Disease

### Diagnosis (IRLSSG Criteria)

Restless legs syndrome is diagnosed based on the International Restless Legs Syndrome Study Group criteria: an urge to move the legs often accompanied by uncomfortable sensations, worsening at rest and with relief from movement, worsening in the evening or nighttime, and not solely explained by another condition such as muscle cramping, positional discomfort, or venous stasis. RLS affects 10 to 15 percent of elderly individuals.

### Secondary Causes (Rule Out)

Before initiating treatment, secondary causes of RLS must be identified and addressed. Iron deficiency is the most important modifiable contributor, and serum ferritin should be checked in all patients with RLS symptoms, with treatment indicated when ferritin is below 75 mcg/L and a target of above 100 mcg/L for RLS management. Intravenous iron may be more effective and better tolerated than oral supplementation. Chronic kidney disease and uremia, peripheral neuropathy, and medication effects (SSRIs, SNRIs, antihistamines, dopamine antagonists including antipsychotics and metoclopramide) are additional secondary causes requiring evaluation.

### Treatment

Iron supplementation is the foundational intervention when ferritin is below 75 mcg/L. Oral ferrous sulfate at 325 mg with vitamin C on an empty stomach is the standard oral regimen, with intravenous iron preferred for patients who are oral-intolerant or have ferritin below 30.

Treatment paradigms for RLS have shifted substantially in recent years. Non-dopaminergic agents are now preferred as first-line pharmacotherapy. Gabapentin enacarbil at 600 mg daily is an FDA-approved sustained-release gabapentin prodrug that provides effective relief without augmentation risk. Pregabalin at 150 to 300 mg at bedtime is effective and similarly free from augmentation. Dopamine agonists, including pramipexole at 0.125 to 0.5 mg and ropinirole at 0.25 to 1 mg at bedtime, were previously considered first-line but are now used cautiously due to the high risk of augmentation, defined as the paradoxical worsening and temporal/spatial spreading of symptoms with chronic use, which occurs in 40 to 70 percent of patients over 10 years. Impulse control disorders, including pathological gambling, compulsive shopping, and hypersexuality, affect 5 to 15 percent of patients on dopamine agonists. Agents that worsen RLS, including diphenhydramine, SSRIs, caffeine, and alcohol, should be avoided.

## REM Sleep Behavior Disorder (RBD)

REM sleep behavior disorder results from the loss of normal muscle atonia during REM sleep, leading to dream enactment behaviors such as punching, kicking, yelling, and running during sleep. It affects 1 to 2 percent of elderly individuals with a male predominance. RBD is one of the strongest prodromal markers for alpha-synucleinopathy, with 80 to 90 percent of patients developing Parkinson disease, dementia with Lewy bodies, or multiple system atrophy within 10 to 15 years.

Diagnosis requires polysomnographic confirmation of REM without atonia (RWA) in conjunction with a history of dream enactment behavior. Treatment centers on melatonin at 3 to 12 mg at bedtime as the first-line intervention due to its favorable safety profile. Clonazepam at 0.25 to 0.5 mg is effective but carries fall and sedation risks in the elderly. Safety measures, including padded bed rails, removal of bedside objects, and consideration of separate sleeping arrangements for the bed partner, are essential components of management. Patients should be counseled about the neurodegenerative risk associated with RBD, with shared decision-making about participation in neuroprotective clinical trials and the importance of ongoing clinical monitoring for emerging parkinsonian or cognitive symptoms.

## Key Clinical Pearls

- CBT-I is first-line for chronic insomnia in elderly — it is more effective than any medication and benefits persist after treatment ends; it should be offered before any sleep medication
- AVOID benzodiazepines and Z-drugs (zolpidem) for insomnia in elderly (Beers criteria) — they increase falls, fractures, cognitive impairment, and delirium
- Dual orexin receptor antagonists (suvorexant, lemborexant) are emerging as the preferred pharmacotherapy when medications are needed — they improve both onset and maintenance without dependence
- Normal aging causes earlier sleep timing and lighter sleep — this is NOT insomnia unless it causes daytime impairment; counsel patients that needing slightly less sleep is normal
- OSA in elderly often presents atypically (cognitive decline, nocturia, insomnia) rather than with classic excessive daytime sleepiness — screen with STOP-BANG
- REM Sleep Behavior Disorder is a red flag for future synucleinopathy (PD, DLB) — 80-90% conversion over 10-15 years; monitor with regular neurological assessment
- RLS treatment has shifted away from dopamine agonists (augmentation risk 40-70%) toward gabapentinoids — always check ferritin and replete iron first

## References
1. Qaseem A, Kansagara D, Forciea MA, et al. Management of chronic insomnia disorder in adults: a clinical practice guideline from the American College of Physicians. *Ann Intern Med*. 2016;165(2):125-133.
2. Sateia MJ, Buysse DJ, Krystal AD, Neubauer DN, Heald JL. Clinical practice guideline for the pharmacologic treatment of chronic insomnia in adults: an AASM clinical practice guideline. *J Clin Sleep Med*. 2017;13(2):307-349.
3. Ohayon MM, Carskadon MA, Guilleminault C, Vitiello MV. Meta-analysis of quantitative sleep parameters from childhood to old age in healthy individuals. *Sleep*. 2004;27(7):1255-1273.
4. Allen RP, Picchietti DL, Auerbach M, et al. Evidence-based and consensus clinical practice guidelines for the iron treatment of restless legs syndrome/Willis-Ekbom disease in adults and children: an IRLSSG task force report. *Sleep Med*. 2018;41:27-44.
5. Postuma RB, Iranzo A, Hu M, et al. Risk and predictors of dementia and parkinsonism in idiopathic REM sleep behaviour disorder: a multicentre study. *Brain*. 2019;142(3):744-759.